Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer’s disease

References

• Alzheimer’s Association As. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 2019;15(3):321–387.
   Web of Science ®Google Scholar
• Europe A. Dementia in Europe Yearbook 2019: estimating the prevalence of dementia in Europe. Alzheimer Europe. 2019.
   Google Scholar
• Scheltens P, Blennow K, Breteler M, et al. Alzheimer’s disease. Lancet (Lond Engl). 2016;388(10043):505–517.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Incorporating clinical outcome assessments into endpoints for regulatory decision making. 2018 https://www.fda.gov/media/132505/download.
   Google Scholar
• Grober E, Hall CB, Lipton RB, et al., Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. J Int Neuropsychol Soc. 2008;14(2):266–278. .
   PubMed Web of Science ®Google Scholar
• Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–292.
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Focus. 2013;11(1):96–106.
   Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021 Mar;17(3):327–406.
   PubMed Web of Science ®Google Scholar
• Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292–323.
   PubMed Web of Science ®Google Scholar
• Schindler SE, Bateman RJ. Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia. Nature Aging. 2021;1(1):26–28.
   Google Scholar
• Ribeiro F, de Mendonça A, Guerreiro M. Mild cognitive impairment: deficits in cognitive domains other than memory. Dement Geriatr Cogn Disord. 2006;21(5–6):284–290.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–308.
   PubMed Web of Science ®Google Scholar
• Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Caracciolo B, Brayne C, et al. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214–228.
   PubMed Web of Science ®Google Scholar
• Jak AJ, Bondi MW, Delano-Wood L, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatric Psychiatry. 2009;17(5):368–375.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126–135.
   PubMed Web of Science ®Google Scholar
• Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic-vs community-based cohorts. Arch Neurol. 2009;66(9):1151–1157.
   PubMedGoogle Scholar
• Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr. 2004;16(2):129–140.
   PubMed Web of Science ®Google Scholar
• Malek-Ahmadi M. Reversion from mild cognitive impairment to normal cognition. Alzheimer Dis Assoc Disord. 2016;30(4):324–330.
   PubMed Web of Science ®Google Scholar
• Brown PJ, Devanand D, Liu X, et al. Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer's disease. Arch Gen Psychiatry. 2011;68(6):617–626.
   PubMed Web of Science ®Google Scholar
• Hoe J, Hancock G, Livingston G, et al. Changes in the quality of life of people with dementia living in care homes. Alzheimer Dis Assoc Disord. 2009;23(3):285.
   PubMed Web of Science ®Google Scholar
• Feldman H, Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology. 2005;65(6 suppl 3):S10–S17.
   Web of Science ®Google Scholar
• Winblad B, Gauthier S, Åström D, et al. Memantine benefits functional abilities in moderate to severe Alzheimer’s disease. J Nutr Health Aging. 2010;14(9):770–774.
   PubMed Web of Science ®Google Scholar
• Moran M, Lynch C, Walsh C, et al. Sleep disturbance in mild to moderate Alzheimer’s disease. Sleep Med. 2005;6(4):347–352.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16(3):391–460.
   Web of Science ®Google Scholar
• Franx BAA, Arnoldussen IAC, Kiliaan AJ, et al. Weight loss in patients with dementia: considering the potential impact of pharmacotherapy. Drugs Aging. 2017 Jun;34(6):425–436.
   PubMed Web of Science ®Google Scholar
• Anderson RM, Hadjichrysanthou C, Evans S, et al. Why do so many clinical trials of therapies for Alzheimer’s disease fail? Lancet. 2017;390(10110):2327–2329.
   PubMed Web of Science ®Google Scholar
• Atri A. Current and Future Treatments in Alzheimer’s Disease. Semin Neurol. 2019 Apr;39(2):227–240.
   PubMed Web of Science ®Google Scholar
• Casey DA, Antimisiaris D, O’Brien J. Drugs for Alzheimer’s disease: are they effective? Pharm Ther. 2010;35(4):208.
   Google Scholar
• Cummings J, Lee G, Zhong K, et al. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dementia. 2021;7(1):e12179.
   Web of Science ®Google Scholar
• Database MC. Decision Memo. National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease. 2022.
   Google Scholar
• Ezzati A, Davatzikos C, Wolk DA, et al. Application of predictive models in boosting power of Alzheimer’s disease clinical trials: a post hoc analysis of phase 3 solanezumab trials. Alzheimer's Dementia. 2022;8(1):e12223.
   Google Scholar
• Gauthier S, Albert M, Fox N, et al., Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12(1):60–64. .
   PubMed Web of Science ®Google Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702–716.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Guidance for industry. Early Alzheimer’s disease. Developing drugs for the treatment (draft guidance) Feb, 2018.
   Google Scholar
• Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–1704.
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer’s Res Ther. 2017;9(1):1–15.
   PubMedGoogle Scholar
• Banks SJ, Qiu Y, Fan CC, et al. Enriching the design of Alzheimer’s disease clinical trials: application of the polygenic hazard score and composite outcome measures. Alzheimer's Dementia. 2020;6(1):e12071.
   Web of Science ®Google Scholar
• Giebel CM, Sutcliffe C, Stolt M, et al. Deterioration of basic activities of daily living and their impact on quality of life across different cognitive stages of dementia: a European study. Int Psychogeriatr. 2014 Aug;26(8):1283–1293.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA work group* under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34(7):939.
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–562.
   PubMed Web of Science ®Google Scholar
• Huang L-K, Chao S-P, C-J H. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):1–13.
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer’s research consortium study. Arch Neurol. 2008;65(8):1091–1095.
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence Draft scope for the appraisal of donepezil, galantamine, rivastigmine & memantine for the treatment of mild to moderate Alzheimer’s disease issue date: September 2009.
   Google Scholar
• Pause BM, Zlomuzica A, Kinugawa K, et al. Perspectives on episodic-like and episodic memory. Front Behav Neurosci. 2013;7:33.
   PubMed Web of Science ®Google Scholar
• Fabrigoule C, Rouch I, Taberly A, et al. Cognitive process in preclinical phase of dementia. Brain. 1998;121(1):135–141.
   PubMed Web of Science ®Google Scholar
• Matsuda O, Saito M. Multiple cognitive deficits in patients during the mild cognitive impairment stage of Alzheimer’s disease: how are cognitive domains other than episodic memory impaired? Int Psychogeriatr. 2009;21(5):970–976.
   PubMed Web of Science ®Google Scholar
• Wechsler D. WAIS-R: Wechsler adult intelligence scale-revised. New York N.Y: Psychological Corporation, [1981] ©1981; 1981.
   Google Scholar
• Devanand D, Folz M, Gorlyn M, et al. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45(3):321–328.
   PubMed Web of Science ®Google Scholar
• Hall CB, Ying J, Kuo L, et al. Estimation of bivariate measurements having different change points, with application to cognitive ageing. Stat Med. 2001;20(24):3695–3714.
   PubMed Web of Science ®Google Scholar
• Ueckert S, Plan EL, Ito K, et al., Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling. Pharm Res. 2014;31(8):2152–2165. .
   PubMed Web of Science ®Google Scholar
• Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer’s disease assessment scale–cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. a narrative review. J Alzheimers Dis. 2018;63(2):423–444.
   PubMed Web of Science ®Google Scholar
• Grober E, Sanders AE, Hall C, et al. Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord. 2010;24(3):284.
   PubMed Web of Science ®Google Scholar
• Delis DC, Kramer JH, Kaplan E, et al. CVLT: California verbal learning test-adult version: manual. San Antonio, TX: Psychological corporation; 1987.
   Google Scholar
• Wilson JR, De Fries J, Mc Clearn G, et al. Cognitive abilities: use of family data as a control to assess sex and age differences in two ethnic groups. Int J Aging Hum Dev. 1975;6(3):261–276.
   PubMed Web of Science ®Google Scholar
• Papp KV, Rentz DM, Orlovsky I, et al. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: the PACC5. Alzheimer's Dementia. 2017;3(4):668–677.
   Google Scholar
• Harrison J, Minassian SL, Jenkins L, et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64(9):1323–1329.
   PubMed Web of Science ®Google Scholar
• Holtzer R, Verghese J, Wang C, et al. Within-person across-neuropsychological test variability and incident dementia. Jama. 2008 Aug 20;300(7):823–830.
   PubMed Web of Science ®Google Scholar
• Zahodne LB, Manly JJ, MacKay-Brandt A, et al. Cognitive declines precede and predict functional declines in aging and Alzheimer’s disease. PLoS One. 2013;8(9):e73645.
   PubMed Web of Science ®Google Scholar
• Delgado C, Vergara RC, Martínez M, et al. Neuropsychiatric symptoms in Alzheimer’s disease are the main determinants of functional impairment in advanced everyday activities. J Alzheimers Dis. 2019;67(1):381–392.
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. the Alzheimer’s disease cooperative study. Alzheimer Dis Assoc Disord. 1997;11(2):S33–9.
   PubMedGoogle Scholar
• Dubbelman MA, Jutten RJ, Tomaszewski Farias SE, et al. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum. Alzheimers Res Ther. 2020 Oct 29;12(1):138.
   PubMed Web of Science ®Google Scholar
• Burton CL, Strauss E, Bunce D, et al. Functional abilities in older adults with mild cognitive impairment. Gerontology. 2009;55(5):570–581.
   PubMed Web of Science ®Google Scholar
• Allaire JC, Gamaldo A, Ayotte BJ, et al. Mild cognitive impairment and objective instrumental everyday functioning: the everyday cognition battery memory test. J Am Geriatr Soc. 2009 Jan;57(1):120–125.
   PubMed Web of Science ®Google Scholar
• Tabira T, Hotta M, Murata M, et al. Age-related changes in instrumental and basic activities of daily living impairment in older adults with very mild Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2020 Jan-Apr;10(1):27–37.
   PubMed Web of Science ®Google Scholar
• Politis AM, Alexopoulos P, Vorvolakos T. May neuropsychiatric symptoms be a potential intervention target to delay functional impairment in Alzheimer’s disease? Int Psychogeriatr. 2020;32(6):689–691.
   PubMed Web of Science ®Google Scholar
• Cahn-Weiner DA, Farias ST, Julian L, et al. Cognitive and neuroimaging predictors of instrumental activities of daily living. J Int Neuropsychol Soc. 2007 Sep;13(5):747–757.
   PubMed Web of Science ®Google Scholar
• Fields JA, Machulda M, Aakre J, et al. Utility of the DRS for predicting problems in day-to-day functioning. Clin Neuropsychol. 2010 Oct;24(7):1167–1180.
   PubMed Web of Science ®Google Scholar
• Giebel CM, Sutcliffe C, Challis D. Activities of daily living and quality of life across different stages of dementia: a UK study. Aging Ment Health. 2015 Jan;19(1):63–71.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Guidance for industry. Alzheimer’s disease. Developing drugs for the treatment of early stage disease (draft guidance) Feb, 2013.
   Google Scholar
• Pedrosa H, De Sa A, Guerreiro M, et al. Functional evaluation distinguishes MCI patients from healthy elderly people—the ADCS/MCI/ADL scale. J Nutr Health Aging. 2010;14(8):703–709.
   PubMed Web of Science ®Google Scholar
• Pfeffer RI, Kurosaki TT, Harrah CH Jr., et al. Measurement of functional activities in older adults in the community. J Gerontol. 1982 May;37(3):323–329.
   PubMedGoogle Scholar
• Ard MC, Galasko DR, Edland SD. Improved statistical power of Alzheimer clinical trials by item-response theory: proof of concept by application to the activities of daily living scale. Alzheimer Dis Assoc Disord. 2013 Apr-Jun;27(2):187–191.
   PubMed Web of Science ®Google Scholar
• Bowling A, Rowe G, Adams S, et al. Quality of life in dementia: a systematically conducted narrative review of dementia-specific measurement scales. Aging Ment Health. 2015 Jan;19(1):13–31.
   PubMed Web of Science ®Google Scholar
• Torisson G, Stavenow L, Minthon L, et al. Reliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatients. Health Qual Life Outcomes. 2016;14(1):1–8.
   PubMedGoogle Scholar
• Ezzati A, Zammit AR, Katz MJ, et al. Health-related quality of life, cognitive performance, and incident dementia in a community-based elderly cohort. Alzheimer Dis Assoc Disord. 2019 Jul-Sep;33(3):240–245.
   PubMed Web of Science ®Google Scholar
• Bárrios H, Narciso S, Guerreiro M, et al. Quality of life in patients with mild cognitive impairment. Aging Ment Health. 2013;17(3):287–292.
   PubMed Web of Science ®Google Scholar
• Weiss EM, Papousek I, Fink A, et al. Quality of life in mild cognitive impairment, patients with different stages of Alzheimer's disease and healthy control subjects. Neuropsychiatr. 2012;26(2):72–77.
   PubMedGoogle Scholar
• Hussenoeder FS, Conrad I, Roehr S, et al. Mild cognitive impairment and quality of life in the oldest old: a closer look. Qual Life Res. 2020 Jun;29(6):1675–1683.
   PubMed Web of Science ®Google Scholar
• Kahle-Wrobleski K, Ye W, Henley D, et al. Assessing quality of life in Alzheimer’s disease: implications for clinical trials. Alzheimers Dement (Amst). 2017;6(1):82–90.
   PubMedGoogle Scholar
• Landeiro F, Mughal S, Walsh K, et al. Health-related quality of life in people with predementia Alzheimer’s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimer’s Res Ther. 2020 November 18;12(1):154.
   PubMed Web of Science ®Google Scholar
• Ecklund-Johnson E, Torres I. Unawareness of deficits in Alzheimer’s disease and other dementias: operational definitions and empirical findings. Neuropsychol Rev. 2005 Sep;15(3):147–166.
   PubMed Web of Science ®Google Scholar
• Karlawish JH, Casarett D, Klocinski J, et al. The relationship between caregivers’ global ratings of Alzheimer’s disease patients’ quality of life, disease severity, and the caregiving experience. J Am Geriatr Soc. 2001 Aug;49(8):1066–1070.
   PubMed Web of Science ®Google Scholar
• Smith S, Lamping D, Banerjee S, et al. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess. 2005;9(10):1–iv.
   Web of Science ®Google Scholar
• Logsdon RG, Gibbons LE, McCurry SM, et al. Quality of life in Alzheimer’s disease: patient and caregiver reports. Aging Ment Health Aging. 1999;5. 21–32.
   Google Scholar
• Dean K, Jenkinson C, Wilcock G, et al. The development and validation of a patient-reported quality of life measure for people with mild cognitive impairment. Int Psychogeriatr. 2014 Mar;26(3):487–497.
   PubMed Web of Science ®Google Scholar
• Savaskan E, Bopp-Kistler I, Buerge M. Therapy guidelines for the behavioural and psychological symptoms of dementia. Praxis (Bern 1994). 2014;103(3):135–148.
   PubMedGoogle Scholar
• Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. Bmj. 2015 Mar 2;350(mar02 7):h369.
   PubMedGoogle Scholar
• Barnes DE, Yaffe K, Byers AL, et al. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry. 2012 May;69(5):493–498.
   PubMed Web of Science ®Google Scholar
• Modrego PJ, Ferrández J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol. 2004 Aug;61(8):1290–1293.
   PubMedGoogle Scholar
• Canevelli M, Adali N, Cantet C, et al. Impact of behavioral subsyndromes on cognitive decline in Alzheimer’s disease: data from the ICTUS study. J Neurol. 2013;260(7):1859–1865.
   PubMed Web of Science ®Google Scholar
• Sundermann EE, Katz MJ, Lipton RB. Sex differences in the relationship between depressive symptoms and risk of amnestic mild cognitive impairment. Am J Geriatric Psychiatry. 2017;25(1):13–22.
   PubMed Web of Science ®Google Scholar
• Pocnet C, Antonietti J-P, Donati A, et al. Behavioral and psychological symptoms and cognitive decline in patients with amnestic MCI and mild AD: a two-year follow-up study. Int Psychogeriatr. 2015;27(8):1379–1389.
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Jama. 2002 Sep 25;288(12):1475–1483.
   PubMed Web of Science ®Google Scholar
• Roberto N, Portella MJ, Marquié M, et al. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Sci Rep. 2021;11(1):1–9.
   PubMed Web of Science ®Google Scholar
• Van der linde RM, Dening T, Stephan BC, et al. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry. 2016;209(5):366–377.
   PubMed Web of Science ®Google Scholar
• Ballard CG, O’Brien JT, Coope B, et al. Psychotic symptoms in dementia and the rate of cognitive decline. J Am Geriatr Soc. 1997 Aug;45(8):1031–1032.
   PubMed Web of Science ®Google Scholar
• Cohen-Mansfield J. Behavioral and psychological symptoms of dementia. 2015.
   Google Scholar
• Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry. 1988 Feb 1;23(3):271–284.
   PubMed Web of Science ®Google Scholar
• Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):10S–16S.
   PubMed Web of Science ®Google Scholar
• Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48 Suppl:9–15.
   PubMed Web of Science ®Google Scholar
• Balardy L, Voisin T, Cantet C, et al. Predictive factors of emergency hospitalisation in Alzheimer’s patients: results of one-year follow-up in the REAL. FR Cohort. J Nutr Health Aging. 2005;9(2): 112–116
   PubMed Web of Science ®Google Scholar
• McIlvane JM, Popa MA, Robinson B, et al. Perceptions of illness, coping, and well-being in persons with mild cognitive impairment and their care partners. Alzheimer Dis Assoc Disord. 2008;22(3):284–292.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Rosenheck R, Lyketsos CG, et al. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatric Psychiatry. 2010;18(10):917–927.
   PubMed Web of Science ®Google Scholar
• Dauphinot V, Delphin-Combe F, Mouchoux C, et al. Risk factors of caregiver burden among patients with Alzheimer’s disease or related disorders: a cross-sectional study. J Alzheimers Dis. 2015;44(3):907–916.
   PubMed Web of Science ®Google Scholar
• Erder MH, Wilcox TK, Chen W-H, et al. A new measure of caregiver burden in Alzheimer’s disease: the caregiver-perceived burden questionnaire. Am J Alzheimer’s Dis Other Dementias®. 2012;27(7):474–482.
   PubMed Web of Science ®Google Scholar
• Hébert R, Bravo G, Préville M. Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Canadian Journal on Aging / La Revue Canadienne du Vieillissement. 2000;19(4):494–507.
   Web of Science ®Google Scholar
• Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group. Lancet Neurol. 2021 Jun;20(6):484–496.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. https://www.fda.gov/downloads/Drugs/NewsEvents/UCM620708.pdf.
   Google Scholar
• Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421–430.
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Perez A, Holland TM, et al. Primary prevention recommendations to reduce the risk of cognitive decline. Alzheimers Dement. 2022 Jan 13;18(8):1569–1579.
   PubMed Web of Science ®Google Scholar
• Assunção SS, Sperling RA, Ritchie C, et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease. Alzheimers Res Ther. 2022 Apr 19;14(1):54.
   PubMed Web of Science ®Google Scholar
• Grober E, Lipton RB, Sperling RA, et al. Associations of stages of objective memory impairment with amyloid PET and structural MRI: the A4 study. Neurology. 2022 Mar 29;98(13):e1327–e1336.
   PubMed Web of Science ®Google Scholar
• Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19;6(228):228fs13.
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Verberk IM, Thijssen EH, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77.
   PubMed Web of Science ®Google Scholar
• Hampel H, Cummings J, Blennow K, et al. Developing the ATX (N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021;17(9):580–589.
   PubMed Web of Science ®Google Scholar
• Wesseling H, Mair W, Kumar M, et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell. 2020;183(6):1699–1713. e13.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA grants accelerated approval for Alzheimer’s drug. 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
   Google Scholar